2023
Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments
Iezzi R, Gangi A, Posa A, Pua U, Liang P, Santos E, Kurup A, Tanzilli A, Tenore L, De Leoni D, Filippiadis D, Giuliante F, Valentini V, Gasbarrini A, Goldberg S, Meijerink M, Manfredi R, Kelekis A, Colosimo C, Madoff D. Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments. Cancers 2023, 15: 308. PMID: 36612304, PMCID: PMC9818393, DOI: 10.3390/cancers15010308.Peer-Reviewed Original ResearchInterventional oncologyLocoregional treatmentCancer patientsNew locoregional treatmentMultiple body systemsLow-risk alternativeImage-guided techniquesLocoregional proceduresSurgical therapyPalliative careInvasive proceduresPotential cureDisease sitesNew indicationsTreatment of diseasesInnovative indicationsOncologyPatientsTreatmentEvidence-reported literatureExpert discussionIndicationsWide spectrumReviewWidespread use
2019
Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing
Wu Y, Warner J, Wang L, Jiang M, Xu J, Chen Q, Nian H, Dai Q, Du X, Yang P, Denny J, Liu H, Xu H. Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing. JCO Clinical Cancer Informatics 2019, 3: cci.19.00001. PMID: 31141421, PMCID: PMC6693869, DOI: 10.1200/cci.19.00001.Peer-Reviewed Original ResearchConceptsVanderbilt University Medical CenterCancer survivalMayo ClinicDrug repurposingNoncancer drugsElectronic health record dataCancer registry dataEHR dataClinical trial evaluationOverall cancer survivalUniversity Medical CenterHealth record dataElectronic health recordsTreatment of cancerClinical trialsDrug classesRegistry dataMedical CenterDrug effectsSignificant associationLongitudinal EHRNew indicationsPatientsCancerHealth recordsAnalysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
Skydel JJ, Luxkaranayagam AT, Dhruva SS, Ross JS, Wallach JD. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments. JAMA Network Open 2019, 2: e193410. PMID: 31074812, PMCID: PMC6512282, DOI: 10.1001/jamanetworkopen.2019.3410.Peer-Reviewed Original ResearchConceptsPostapproval clinical trialsClinical trialsPrimary completion datePostmarketing requirementsNovel therapeuticsDrug AdministrationUS FoodNew indicationsPharmaceutical companiesNew clinical studiesCross-sectional analysisClinical outcomesStudy design elementsPatient populationUnapproved indicationsEfficacy dataClinical studiesStudy completionMAIN OUTCOMEFirst approvalMost trialsTrialsFDATherapeutic approvalsTherapeuticsTreatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends.
Rosenthal K, Galsky M, Milowsky M, Petrylak D, Rosenberg J, Obholz K, Plimack E. Treatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends. Journal Of Clinical Oncology 2019, 37: 389-389. DOI: 10.1200/jco.2019.37.7_suppl.389.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCisplatin-based chemotherapyMetastatic urothelial carcinomaUrothelial carcinomaHealthcare providersExact testDifferent immune checkpoint inhibitorsPD-L1 testingFischer's exact testFDA label changePearson chi-squaredEligible ptsCheckpoint inhibitorsEligible casesTreatment indicationsTreatment decisionsClinical practicePractice trendsNew indicationsExpert recommendationsChi-squaredCarcinomaLabel changes
2016
Prescribing “Off-Label”: What Should a Physician Disclose?
Furey K, Wilkins K. Prescribing “Off-Label”: What Should a Physician Disclose? The AMA Journal Of Ethic 2016, 18: 587. PMID: 27322992, DOI: 10.1001/journalofethics.2016.18.6.ecas3-1606.Peer-Reviewed Original Research
2006
New Trends in Breast Cancer Management
Pomahac B, Recht A, May J, Hergrueter C, Slavin S. New Trends in Breast Cancer Management. Annals Of Surgery 2006, 244: 282-288. PMID: 16858192, PMCID: PMC1602160, DOI: 10.1097/01.sla.0000217626.88430.c3.Peer-Reviewed Original ResearchConceptsBreast reconstructionPostoperative radiotherapyPostoperative radiation therapyImmediate breast reconstructionSentinel node biopsyBreast cancer managementNew treatment algorithmDelayed-immediate reconstructionLatissimus dorsi flapPostmastectomy radiationNode biopsyFree TRAMTreatment algorithmImmediate reconstructionDelayed reconstructionBlood supplyCancer managementRadiation therapyReconstructive optionsPerforator flapReconstruction optionsNew indicationsContralateral componentRadiotherapyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply